Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67591193

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
HomeProductsAPIs And IntermediatesRuxolitinib Intermediates
PRODUCT CATEGORIES

Ruxolitinib Intermediates

(Total 5 Products)
Ruxolitinib intermediates CAS NO.941678-49-5

Unit PriceUSD 1 / Kilogram

Min.Order Unit Price
1 Kilogram USD 1 / Kilogram

Packaging: As required

Supply Ability: Stock available

Purity:99.0%+ Package&Shipping Package:Double PE Bag with Foil Bag or As Required Delivery time:Stock Available Port:Any port in China
Ruxolitinib intermediates CAS NO.941685-26-3

Unit PriceUSD 1 / Kilogram

Min.Order Unit Price
1 Kilogram USD 1 / Kilogram

Packaging: AS REQUIRED

Supply Ability: STOCK AVAILABLE

Purity:98.0%+ Package&Shipping Package:Double PE Bag with Foil Bag or As Required Delivery time:Stock Available Port:Any port in China
Ruxolitinib intermediates CAS NO.1146629-75-5

Unit PriceUSD 1 / Kilogram

Min.Order Unit Price
1 Kilogram USD 1 / Kilogram

Packaging: AS REQUIRED

Supply Ability: STOCK AVAILABLE

Purity:98.0%+ Package&Shipping Package:Double PE Bag with Foil Bag or As Required Delivery time:Stock Available Port:Any port in China
Ruxolitinib Intermediate CAS NO. : 1153949-38-2

Unit PriceUSD 1 / Kilogram

Min.Order Unit Price
1 Kilogram USD 1 / Kilogram

Packaging: AS REQUIRED

Supply Ability: STOCK AVAILABLE

Purity:98.0%+ Package&Shipping Package:Double PE Bag with Foil Bag or As Required Delivery time:Stock Available Port:Any port in China
Ruxolitinib intermediates 3-Cyclopentylacrylonitrile CAS NO. 591769-05-0

Unit PriceUSD 1 / Kilogram

Min.Order Unit Price
1 Kilogram USD 1 / Kilogram

Packaging: AS REQUIRED

Supply Ability: STOCK AVAILABLE

Purity:98.0%+ Package&Shipping Package:Double PE Bag with Foil Bag or As Required Delivery time:Stock Available Port:Any port in China

China Ruxolitinib Intermediates Suppliers

Ruxolitinib (also known as Rucotinib) is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-thrombocythemia essential myelofibrosis. ruxolitinib (Jakavi), an oral JAK1 and JAK2 tyrosine kinase inhibitor, was approved in the EU in August 2012 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis. Myelofibrosis after polycythemia vera and essential thrombocythemia.
Home > Products > APIs And Intermediates > Ruxolitinib Intermediates

New Products

Related Products List

Home

Product

Phone

About Us

Inquiry

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Send